GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Research & Development

Paion Ag (Paion Ag) Research & Development : $5.42 Mil (TTM As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Paion Ag's Research & Development for the six months ended in Jun. 2023 was $1.79 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was $5.42 Mil.

Paion Ag Research & Development Historical Data

The historical data trend for Paion Ag's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Research & Development Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.84 14.55 12.52 5.93 6.87

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.51 2.64 3.23 3.64 1.79

Paion Ag Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion Ag  (OTCPK:PAIOF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Paion Ag Research & Development Related Terms

Thank you for viewing the detailed overview of Paion Ag's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Paion Ag (Paion Ag) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Research & Development
Comparable Companies
FRA:SPB HAM:GWK3 STU:DWB FRA:BBI HAM:TLG ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507 NSE:DIVISLAB BOM:500124 BOM:532321
Traded in Other Exchanges
PA8:Germany
Address
Heussstrasse 25, Aachen, DEU, 52078
Website
https://www.paion.com
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.